Skip to content
Open in App
Takeda Pharma ADR logo

Takeda Pharma ADR

web2

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, market...

Symbol · TAK
Company profile

About

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

Orzeyful approved in China for narcolepsy type 1

KEY STEP

China’s National Medical Products Administration approved Orzeyful, or oveporexton, for narcolepsy type 1 in adolescents aged 16 years and older and adults. This was the medicine’s first regulatory approval.

Roadmap reference

Orzeyful approved in the United States for narcolepsy type 1

KEY STEP

The United States FDA approved Orzeyful, or oveporexton, for adults with narcolepsy type 1. Commercial availability remained subject to Drug Enforcement Administration controlled substance scheduling.

Roadmap reference

Orzeyful approved in Japan for narcolepsy type 1

KEY STEP

Japan’s Ministry of Health, Labour and Welfare approved Orzeyful, or oveporexton, for adults with narcolepsy type 1, marking the medicine’s third major market approval.

Roadmap reference

Mimrylo approved in the United States for polycythemia vera

KEY STEP

The United States FDA approved Mimrylo, or rusfertide, for the treatment of erythrocytosis in adults with polycythemia vera, moving a second major Takeda pipeline asset into commercialization.

Roadmap reference
People

Company team

BD

Bruce Dale Broussard

Independent External Director

Company leadership profile.

MI

Masami Iijima

Independent External Chair

Company leadership profile.

JK

Julie Kim

CEO, President & Director

Company leadership profile.

MF

Milano Furuta

CFO & Director

Company leadership profile.

AS

Andrew S. Plump

President of Research & Development and Representative Director

Company leadership profile.

JM

John Michael Maraganore

Independent External Director

Company leadership profile.

KK

Koichiro Kimura

Independent External Director

Company leadership profile.

SS

Steven S. Gillis

Independent External Director

Company leadership profile.

KA

Kimberly A. Reed

Independent External Director

Company leadership profile.

MT

Miki Tsusaka

Independent External Director

Company leadership profile.

PA

Paulus A. Stoffels

Independent External Director

Company leadership profile.

Expert coverage

2 experts evaluated Takeda Pharma ADR.

Orbitrum research

Experts evaluating Takeda Pharma ADR

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment